User interaction across cross-environment applications through an extended graphics context

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Z124 patent solves the following problem:

This application relates generally to the field around the mobile computing, and especially to support many user environment through the use of multiple operating systems on a single mobile computing device.

Our analysis of this patent is as follows:

Z124’s patent US 8933949 B2 deals with User interaction across cross-environment applications through an extended graphics context.
Cross-around providing support and companionship user to provide a seamless computing experience in a multi-operating system environment Computing. The multi-operating system computing environments may include a mobile operating system and a desktop operating system running simultaneously and independently on a shared grain on a mobile device Computing. User interaction management support includes input events initially shared grain received by receiving input events in desktop operating systems and translation, mapping, and / or through the event input through a virtual input device to mobile operating system as the application of mobile operating systems to receive the input events as if coming from a user interaction in the mobile operating system. The mobile computing device may be a smartphone running the Android mobile operating system and a complete desktop Linux distribution on a modified Android kernel.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Merck Sharp & Dohme Corp. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 8796310 B2 deals with Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors.
invention provides certain amino-pyridine-containing compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, P3, R4, R5, R6, R7, R8, R9, and n are as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Compositions comprising signal peptide-containing proteins

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Incyte Corporation patent solves the following problem:

Protein transport is essential for cellular function. Transport in a protein may be mediated by a peptide signal located at the amino terminal protein itself. The signal peptide consists of ten to twenty hydrophobic amino acids that target the nascent protein from ribosome to a particular membrane bound compartment such as the endoplasmic reticulum (ER). Protein target the ER to continue by way secretory or stay in any of the secretory organelles such as the ER, Golgi apparatus, or lysosomes. Proteins that transit through the secretory way be secreted into the extracellular space or left in the plasma membrane. Secreted proteins are often synthesized as inactive precursors because of the post-translation processing events during transit through the secretory way. Such events include glycosylation, phosphorylation, proteolysis, and removal of the signal peptide with a signal peptidase. The other events that occur during the transport proteins include chaperone-dependent expression and folding of nascent proteins and protein interaction with a receptor or pore complex. Examples of secreted proteins with amino terminal signal peptide described below and include the receptor, extracellular matrix molecules, cytokines, hormones, growth and diversity factor, neuropeptides, vasomediators, phosphokinases, phosphatases, phospholipases, phosphodiesterases, G and Ras-related protein, Ion channels, pedagogue / pump, proteases, and transcription factors. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of the Cell, garland Publishing, New York, NY, pp. 557-560, 582-592.)

Our analysis of this patent is as follows:

Incyte Corporation’s patent US 8716445 B2 deals with Compositions comprising signal peptide-containing proteins.
human invention provides signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. invention also provides expression vector, host cells, antibodies, agonists and antagonists. invention also provides methods for diagnosing, treating, or preventing diseases associated with expression of HSPP.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Integrated emergency medical database system

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Golden Hour Data Systems, Inc. patent solves the following problem:

This invention relates to an integrated system of medical database. More specifically, this invention relates to a medical database for emergency medical transportation industry.

Our analysis of this patent is as follows:

Golden Hour Data Systems, Inc.’s patent US 8712793 B2 deals with Integrated emergency medical database system.
An integrated medical database system for business emergency medical transportation disclosed. The system includes a dispatch module, clinical module, administration module and billing module. Each module to communicate data with one or more other modules to form a system for use in data sharing, thus achieving an end-to-end automation emergency care in medical accounting. Internal consistency checks made by the system to ensure that proper treatments made according to a choice diagnosis.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Determining the capability of a test compound to affect solid tumor stem cells

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The The Regents Of The University Of Michigan, , Oncomed Pharmaceuticals, Inc. patent solves the following problem:

Cancer remains the number two cause of death in this country, resulting in more than 500,000 deaths each year. Despite progress in detection and treatment, cancer mortality remains high. Despite remarkable progress in understanding the molecular basis of cancer, this knowledge has not yet translated into effective therapeutic strategies.

Our analysis of this patent is as follows:

The Regents Of The University Of Michigan, , Oncomed Pharmaceuticals, Inc.’s patent US 8420885 B2 deals with Determining the capability of a test compound to affect solid tumor stem cells.
A small percentage of cells in a firm with strong tumor properties of stem cells. These strong tumor stem cells give rise to two more tumor stem cells and the majority of tumor cells that have lost the capacity for growth and the ability to give rise to new tumors. Therefore, strong tumor heterogeneity appeared before the tumor cell line arising from a strong tumor stem cells. A xenograft model in which we can build in tumors from primary tumors by injection of tumor cells in mammary England severely immunodeficient mice. These xenograft assay allows us to do the biological and molecular assays virtue clonogenic strong tumor stem cells. We also found evidence that strongly implicates the notch road, especially to notch 4, as playing a central pathway of carcinogenesis.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Aerodynamic drag reduction device for a trailer

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Raimund Pfaff patent solves the following problem:

This invention relates to a flying drag reduction device for a trailer, and especially flying a drag reduction device that positions the underside of the trailer forwardly rear wheel assembly to reduce the air flow impingement behind the wheel assembly.

Our analysis of this patent is as follows:

Raimund Pfaff’s patent US 8322778 B1 deals with Aerodynamic drag reduction device for a trailer.
A drag reduction device for a trailer comprising a generally U-shaped upstanding wall means having a floor and the lower ends. devices and the underside of the trailer so that the back end of the device positioned forwardly beyond the end of the rear wheel assembly of the trailer. In some photos, the device with the slider axle trailer so that the device is moved forwardly and rearwardly slider axle.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Nutritional composition comprising immunoglobulins and oligosaccharides

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The N. V. Nutricia patent solves the following problem:

The respiratory tract and intestinal tract are common places for infection with pathogens. Despite the multitude of organisms that often have a functioning immune system, the respiratory and intestinal tract frequently become infected because they are in direct contact with the physical environment and are exposed to pathogenic microorganisms (such as virus , bacteria, protozoa, fungi, etc.) to be transmitted eg touching, the air and by eating. There are many microorganisms that cause disease in children and other people. For individuals whose immune system is compromised the risk of infection and serious illness is higher.

Our analysis of this patent is as follows:

N. V. Nutricia’s patent US 8277835 B2 deals with Nutritional composition comprising immunoglobulins and oligosaccharides.
The present invention provides a method and composition for the treatment and / or prevention of infection, said method comprising orally administering a composition to a mammal, said composition comprising a galactose having containing indigestible oligosaccharide and immunoglobulin from milk or colostrum from hyperimmunized cows.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Intestinal barrier integrity

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The N. V. Nutricia patent solves the following problem:

The stomach epithelium often acts as a barrier authority chose the absorption of nutrients, electrolytes and water and preventing the exposure to dietary and microbial antigens, including food allergens. The stomach epithelium limits the passage of antigens to the systemic circulation, which can cause inflammatory reactions, such as allergic reactions. As the incidence of allergies, especially food allergies is increasing, many research groups search for (preventive) cures for these diseases.

Our analysis of this patent is as follows:

N. V. Nutricia’s patent US 8252769 B2 deals with Intestinal barrier integrity.
the invention of a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: eicosapentaenoic acid (EPA), docosahexacnoic acid (DHA) and arachidonic acid (ARA), and at least two different oligosaccharides.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Prebiotic compositions

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Nestec S.A. patent solves the following problem:

Our analysis of this patent is as follows:

Nestec S.A.’s patent US 8241658 B2 deals with Prebiotic compositions.
The present invention concerns nutritional composition containing oligosaccharides for controlling inflammatory bowel disease and related diseases, such as diarrhea and constipation.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Infant nutritional compositions for preventing obesity

File for Quick & Easy Patent Protection with PowerPatent.

The N.V. Nutricia patent solves the following problem:

Breast-feeding is the preferred method of infant feeding. However, there are circumstances that make breast-feeding impossible or less attractive. In the case of children's formula is a good alternative. The composition of modern infant formulas is adapted in such a way that will meet many of the special nutritional needs of the fast growing and developing infant.

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 8119142 B2 deals with Infant nutritional compositions for preventing obesity.
The present invention relates to a method for the prevention of obesity in later life by administering a nutritional composition to an infant aged between 0 and 36 months. The composition contains linoleic and alpha-linolenic acid.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.